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Introduction
Prader-Willi syndrome (PWS) causes severe obesity, with 
affected individuals displaying profound food-seeking behavior 
(1, 2). People affected by PWS progress along a complex natural 
history with distinct phases, commencing with an early “fail-
ure to thrive” characterized by hypotonia and feeding difficul-
ties. Hyperphagia, decreased energy expenditure, and obesity 
appear later in childhood (3). PWS is typically associated with 
large deletions on human chromosome 15; however, recent 
patient reports have shown that microdeletions encompassing 
the SNORD116 cluster of noncoding RNAs (ncRNAs) on pater-
nal chromosome 15q11.2 result in a phenotype that overlaps 
substantially with PWS (4–8). These patients display most of the 
major diagnostic features of PWS (9, 10), thereby suggesting a 
PWS minimal deletion region encompassing SNORD116 and 2 
neighboring ncRNAs, RNAs IPW and SNORD109A (Supplemen-
tal Figure 1; supplemental material available online with this 
article; https://doi.org/10.1172/JCI97007DS1).
The SNORD116 genomic locus encodes multiple species of 
ncRNAs, including long noncoding RNAs (lncRNAs), arrays of 
small nucleolar RNAs (snoRNAs), and lncRNAs with snoRNA 
ends (sno-lncRNAs), the function of which remains largely 
unknown (11–13). The Prader-Willi region on human chromo-
some 15 is syntenic to mouse chromosome 7, with the SNORD116 
cluster in both species comprising an imprinted array of snoRNA 
repeats interspersed by exons of an lncRNA host gene, 116HG 
(12, 14). SNORD116/Snord116 is also transcribed as part of a 
large transcriptional unit denoted as small nucleolar host gene 14 
(SNHG14, formerly LNCAT) in both humans and mice. The pro-
gression of transcription through SNHG14 is different between 
neuronal and nonneuronal cells (15–17), and in mice, expression 
of Snord116 snoRNAs becomes enhanced within hypothalamic 
nuclei by weaning age (18).
None of the existing mouse models of PWS fully recapitulate 
the human phenotype (19). Many such models with gene dele-
tions in the Prader-Willi region are lethal at the embryonic stage 
or have poor postnatal survival. Two viable mouse lines removing 
Snord116 have been reported: a 150-kb deletion of the Snord116 
cluster from the paternal allele yielding the Snord116+/–P mouse 
(20) and a deletion of Snord116 with 2 exons of the neighboring 
ncRNA (21). In both models, there is no expression of any Snord116 
transcripts, as the maternal allele is silenced by imprinting. Mice 
with a maternal allele Snord116 deletion are, unsurprisingly, indis-
tinguishable from WT controls. Several additional Snord116 dele-
tion models have also been reported, including Snord116 deletions 
that are biallelic (22), specific to neuropeptide Y (NPY) neurons 
(22), or tamoxifen inducible (23).
Profound hyperphagia is a major disabling feature of Prader-Willi syndrome (PWS). Characterization of the mechanisms that 
underlie PWS-associated hyperphagia has been slowed by the paucity of animal models with increased food intake or obesity. 
Mice with a microdeletion encompassing the Snord116 cluster of noncoding RNAs encoded within the Prader-Willi minimal 
deletion critical region have previously been reported to show growth retardation and hyperphagia. Here, consistent with 
previous reports, we observed growth retardation in Snord116+/–P mice with a congenital paternal Snord116 deletion. However, 
these mice neither displayed increased food intake nor had reduced hypothalamic expression of the proprotein convertase 1 
gene PCSK1 or its upstream regulator NHLH2, which have recently been suggested to be key mediators of PWS pathogenesis. 
Specifically, we disrupted Snord116 expression in the mediobasal hypothalamus in Snord116fl mice via bilateral stereotaxic 
injections of a Cre-expressing adeno-associated virus (AAV). While the Cre-injected mice had no change in measured energy 
expenditure, they became hyperphagic between 9 and 10 weeks after injection, with a subset of animals developing marked 
obesity. In conclusion, we show that selective disruption of Snord116 expression in the mediobasal hypothalamus models the 
hyperphagia of PWS.
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ies also report that Snord116+/–P mice 
appear to be hyperphagic.
Recently Burnett et al. have reported 
a human model of PWS using human 
iPS cell–derived (iPSC-derived) neurons 
(24). They report that such neurons, with 
deletions encompassing Snord116, show 
reduced expression of PCSK1 (encod-
ing prohormone covertase), which has 
been previously implicated in human 
obesity (25), and a transcription factor 
NHLH2, which regulates expression of 
the PCSK1 gene (26, 27).
In the present study, we assessed 
energy intake phenotypes in the con-
genital Snord116+/–P mouse and found 
that differences in food intake are not 
significant when corrected appropri ately 
for the effect of lower body weight. 
Deletion of Snord116 specifically in 
the mediobasal hypothalamus of adult 
mice, however, revealed hyperphagia in 
the absence of early effects on growth. 
Of note, a subset of such animals devel-
oped marked obesity.
Results
Congenital paternal Snord116 deletion 
(Snord116+/–P) mice have impaired growth, 
but do not develop hyperphagia or obesity. 
We investigated growth, body compo-
sition, and food intake phenotypes in 
mice with a congenital paternal deletion 
of Snord116 (Snord116+/–P). As previously 
reported, Snord116+/–P mice had signifi-
cantly lower body weight than WT lit-
termates from early postnatal life (P16), 
which continued though adulthood 
(Figure 1, A and B). Similar results were 
also observed in female mice (Supple-
mental Figure 2). Snord116+/–P mice thus 
remain small without transitioning to 
developing obesity. Adult Snord116+/–P 
mice had reduced lean and fat mass as 
assessed by dual-energy x-ray absorpti-
ometry (DEXA) (Figure 1C).
We next determined whether con-
genital Snord116 deficiency may affect food consumption in adult 
mice. However, differences in body size needed to be taken into 
account. Previous reports accounted for these differences by divid-
ing food intake by body weight (20, 22, 28, 29). When daily food 
intake measurements over a 10-day period were divided by total 
body weight in our study, we observed, as others had previously, 
significantly increased food intake in the Snord116+/–P mice (Figure 
1D). The raw food intake data are shown in Supplemental Figure 3.
Considering that there is an inherent difference in body weight 
between Snord116+/–P and WT mice, we hypothesized that it is poss-
All Snord116 deletion mouse models reported thus far 
remain smaller than controls through adulthood and do not 
transition to obesity as seen in human PWS — a summary of 
Snord116 deletion model phenotypes is presented in Supple-
mental Table 1, with focus on growth and energy homeostasis. 
The most consistent phenotype observed in Snord116-deficient 
mice is low body weight and early growth retardation, remi-
niscent of failure to thrive in PWS infants. Differences in body 
weight start emerging between P2 and P5, and body length and 
fat mass are also reported to be diminished. A number of stud-
Figure 1. Congenital Snord116 deletion mice display a growth phenotype, but do not transition to 
obesity or hyperphagia. (A) Postnatal body weight is lower in Snord116+/–P (n = 7) versus WT (n = 3) mice, 
measured to 20 days after birth. Significant weight differences were observed from day 16. **P < 0.01; 
***P < 0.001, 2-way repeated-measures ANOVA. (B) Adult body weight in Snord116+/–P (n = 19) mice 
remains below that of WT (n = 18) mice, measured between 3 and 16 weeks of age, with significant effect 
of genotype on body weight observed throughout adulthood. P < 0.001, 2-factor mixed-design ANOVA. 
(C) All mass subcomponents are decreased in Snord116+/–P (n = 12) versus WT (n = 10) mice, as measured in 
adult males 13 to 16 weeks of age. ****P < 0.0001, t test. (D–F) Analysis of daily food intake (10-day aver-
age) in Snord116+/–P (n = 12) versus WT (n = 10) mice at 13–16 weeks of age reveals that, (D) when divided 
by body weight, food intake is significantly higher in Snord116+/–P mice (t test, P = 0.0026); however, 
when food intake is (E) plotted in relation to body weight as a covariate and (F) ANCOVA-corrected for 
differences in body weight, there is no evidence for altered food intake between WT and Snord116+/–P mice 
(ANCOVA, P = 0.378). Data are reported for male mice as mean ± SEM.
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(24), we examined hypothalamic expression of both genes in 
Snord116+/–P mice. Pcsk1 and Nhlh2 mRNA were detectable in all 4 
hypothalamic nuclei. No differences in expression were observed 
by genotype or nutritional status within any of the 4 nuclei (para-
ventricular nucleus [PVN], ARC, ventromedial hypothalamus 
[VMH], or dorsomedial hypothalamus [DMH]) (Figure 2, C and 
D). These data were confirmed in RNA extracts from whole hypo-
thalami obtained from a different set of experimental animals, 
which also demonstrated that there was no evidence of differen-
tial expression of Pcsk1 and Nhlh2 between WT and Snord116+/–P 
mice in either fed or fasted states (Supplemental Figure 6).
Adult-onset deletion of Snord116 in the mediobasal hypothalamus 
results in hyperphagia, with a subset of mice further developing obe-
sity and increased fat mass. An adult-onset mediobasal hypotha-
lamic deletion of Snord116 was generated by stereotaxic injection 
of AAV-Cre (where AAV indicates adeno-associated virus) into 
Snord116fl mice at 10 weeks of age, with AAV-GFP–injected mice 
used as controls. Successful bilateral targeting of Cre for each 
mouse was verified using Cre immunohistochemistry (Figure 3A). 
Of 26 AAV-Cre injections, 21 were verified as hits, with bilateral 
expression of Cre in the mediobasal hypothalamus, while 5 were 
excluded from analysis as misses, with no bilateral hypothalamic 
expression of Cre. Cre expression in all hits and misses is docu-
mented in Supplemental Figure 7. Efficacy of the Cre-mediated 
deletion of Snord116 was verified in a separate set of AAV-Cre–
injected (n = 10) and AAV-GFP–injected (n = 9) mice, with a reduc-
tion of Snord116 expression in the mediobasal hypothalamus of 
Cre-injected mice (28%, P = 0.01, Student’s t test), but not in other 
regions, including the PVN and cerebral cortex (Figure 3B).
Food intake and energy expenditure were assessed in the post-
surgery period. Food intake was measured over 2 time points: first, 
between 2 and 4 weeks after surgery, when no weight differences 
were evident between the Cre- versus GFP-injected mice, and sec-
ond, between 9 and 10 weeks after surgery, when some Cre-injected 
mice showed increased body weight compared with controls. 
ible that the lower body weight of the Snord116+/–P mice may account 
for the relative differences in food intake. An improved method, based 
on analysis of covariance (ANCOVA), has been reported to better 
model energy homeostasis phenotypes under these circumstances 
(30). This allows us to test whether a difference in food intake exists 
when we remove the confounding effect of body weight. Snord116+/–P 
mice did not have significantly different 24-hour food intake com-
pared with WT mice after differences in body weight were accounted 
for using this model (ANCOVA, P = 0.378) (Figure 1, E and F).
We also studied food intake after a 24-hour fast in Snord116+/–P 
versus WT mice. Using ANCOVA to correct for body-weight dif-
ferences, there were no differences in food intake after either 4 
hours (P = 0.714, ANCOVA) or 24 hours (P = 0.856, ANCOVA) 
after reintroduction of food (Supplemental Figure 4).
Expression of leptin/melanocortin pathway genes in the hypo-
thalamus of Snord116+/–P mice across fed and food-deprived states 
remains normal. To assess whether Snord116 deficiency affects 
the expression of hypothalamic genes in appetitive pathways, 
we evaluated expression of leptin/melanocortin pathway genes. 
RNA-sequencing (RNA-seq) was performed using RNA extracted 
from laser-captured hypothalamic nuclei from adult (16 to 19 
weeks old) WT and Snord116+/–P mice in either the ad libitum–
fed or 24-hour fasted states (Figure 2A). We verified that laser- 
capture microdissection yielded material specific to the dissected 
nucleus by verifying enriched expression of positive control genes 
(Supplemental Figure 5). Within the arcuate nucleus (ARC), the 
expression of Npy, leptin receptor (Lepr), and agouti-related pro-
tein (Agrp) showed the expected increase with fasting in both WT 
and Snord116+/–P mice (FDR < 0.03). Proopiomelanocortin (Pomc) 
also displayed a trend for a decreased expression with fasting in 
both WT (log2 fold change [FC] = –0.52, P < 0.03, FDR = 0.53) and 
Snord116+/–P (log2 FC = –0.67, P < 0.003, FDR = 0.23) mice (Figure 
2B). Following from recent work suggesting that Snord116 defi-
ciency disrupts expression of prohormone convertase 1 (Pcsk1) 
and its transcription activator, nescient helix-loop-helix 2 (Nhlh2) 
Figure 2. Expression of hypothalamic leptin/ 
melanocortin pathway genes is unaltered in congeni-
tal Snord116 deletion compared with that in WT mice 
in both the ad libitum–fed and 24 hour–fasted states. 
(A) Representative image of laser-captured nuclei from 
mouse hypothalamus (cresyl violet stained). Original 
magnification, ×50. (B) The nutritionally regulated 
expression pattern of Pomc, Npy, Lepr, and Agrp does 
not change in congenital Snord116 deletion mice in the 
ARC. Genotype by nutritional state interaction for the 
3 genes is not significant. P > 0.6, FDR = 1, Benjamini-
Hochberg FDR procedure. Expression of (C) Pcsk1 and 
(D) Nhlh2 does not significantly differ by genotype or 
nutritional state (ad libitum fed versus 24 hour fasted) 
across 4 different laser-captured hypothalamic nuclei. 
For B–D, expression is shown for male mice 16–19 weeks 
of age (n = 4–6 mice per condition) as log2 counts per 
million (CPM), with box plots showing the median, 
interquartile range, and extrema.
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(Figure 4B), and at 10 weeks after surgery, a subset (5/21) of AAV-
Cre–treated mice gained over 140% of presurgery weight (Figure 
4C). Mice in this obese AAV-Cre–treated subset appeared obvi-
ously larger than AAV-GFP controls (Figure 4D). Body composition 
was analyzed (DEXA) at 10 weeks after surgery, with increased fat 
mass underlying the obesity of a subset of Cre-treated mice (Figure 
4E and Supplemental Figure 8).
Snord116fl Cre-injected mice have normal hypothalamic 
leptin-melanocortin gene expression, with obese animals displaying 
increased Socs3 expression. We analyzed whether the hyperpha-
gic phenotype observed in the AAV-Cre–targeted mice may be 
driven by altered expression of hypothalamic genes in appetitive 
pathways. RNA-seq was performed on laser-captured hypotha-
lamic regions obtained from adjacent brain sections with Cre 
immunohistochemistry as well as matching regions from AAV-
GFP–injected mice. For the AAV-Cre mice, we analyzed gene 
expression in mice that were from the obese (>140% presurgery 
body weight) and nonobese subsets. No significant changes were 
detected in the expression of Pomc, Lepr, Npy, Agrp, Pcksk1, or 
Energy expenditure was measured at 6 weeks after surgery, when 
differences in weight between the Cre- and GFP-injected mice 
began to appear. There were no detectable differences between 
Cre- and GFP-injected mice when measured between 2 and 4 
weeks after surgery (P = 0.084, ANCOVA) (Figure 3C). Differences 
in energy expenditure as measured through indirect calorimetry 
were not significant when assessed at 6 weeks after surgery (P = 
0.348, ANCOVA) (Figure 3D). Food intake studies performed 
between 9 and 10 weeks after surgery revealed consistent hyper-
phagia in Cre-injected mice regardless of body weight (P = 0.001, 
ANCOVA) (Figure 3E).
Body weight and composition were also assessed over the 
10-week postsurgery period. AAV-Cre–injected mice gained more 
weight (as a percentage of presurgery weight) compared with 
AAV-GFP–injected controls (P = 0.016, ANOVA), with differences 
appearing from 6 weeks after surgery (Figure 4A). Analysis of the 
individual body-weight curves highlighted greater variability in the 
weight gain of AAV-Cre–injected mice (final weight, 29.8–42.8 g) 
compared with AAV-GFP–injected mice (final weight, 28.8–35.8 g) 
Figure 3. Adult-onset deletion of Snord116 in the mediobasal hypothalamus results in hyperphagia with no alteration in energy expenditure. (A) Bilateral 
targeting of the mediobasal hypothalamus was performed with AAV-Cre injection and verified with Cre immunohistochemistry. 3V, third ventricle. Original 
magnification, ×200. (B) Micropunches of 3 brain regions revealed a selective decrease of Snord116 expression in the mediobasal hypothalamus in AAV-Cre–
injected (n = 10) mice (28% decrease, P = 0.01, t test) compared with AAV-GFP controls (n = 9). Bars display mean ± SEM. (C) Ten-day average food intake  
measured from 2 weeks after stereotaxic surgery was not significantly different between AAV-GFP– and AAV-Cre–treated mice (P = 0.084, ANCOVA). (D) No 
differences in energy expenditure were observed over 72-hour indirect calorimetry commencing 6 weeks after viral delivery (P = 0.348, ANCOVA). (E) Signifi-
cantly higher food intake (corrected for the covariate of body weight) was observed in AAV-Cre–treated mice versus AAV-GFP–treated controls (P = 0.001, 
ANCOVA) when measured over 5 days commencing 9 weeks after viral delivery. For C–E, top panels display scatter plots of body weight versus either food 
intake or energy expenditure and bottom panels display food intake/energy expenditure values that are ANCOVA-corrected for body weight (estimated mar-
ginal mean ± SEM). All data are reported for male mice, with surgery commencing at 10 to 12 weeks of age.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
9 6 4 jci.org   Volume 128   Number 3   March 2018
test) in all AAV-Cre hits compared with that in GFP-injected con-
trols (Supplemental Figure 9A). No significant differences were 
detected in levels of testosterone or IGF-1 (Supplemental Figure 9, 
B and C).
Discussion
Small deletions encompassing the SNORD116 cluster result in a phe-
notype substantially overlapping with PWS in humans, commencing 
with an early failure to thrive and with a later onset of hyperphagia 
and obesity. Limited aspects of the PWS phenotype have, however, 
been recapitulated with deletions of Snord116 in mice.
Consistent with previous reports (20, 22, 28), we observed 
impaired growth in congenital Snord116+/–P mice from early post-
Nhlh2 (for all genes, FDR > 0.38) (Figure 5, A–F). In obese AAV-
Cre–treated mice compared with AAV-GFP–injected controls, we 
observed increased expression of suppressor of cytokine signal-
ing 3 (Socs3) (FDR = 0.08) (Figure 5G), a gene that has been sug-
gested to affect hypothalamic signaling pathways downstream of 
leptin (31, 32). Cre and Gfp expression was, as expected, observed 
only in the samples of those specific treatment groups (Figure 5, 
H and I). Complete lists of differentially expressed genes are pro-
vided in Supplemental Table 2.
We further assayed serum collected at 10 weeks after surgery 
to assess physiological changes that may accompany adult hypo-
thalamic Snord116 deletion. A small but significant difference in 
total thyroxine (T4) was observed (P = 0.005, Mann-Whitney U 
Figure 4. A subset of Cre-targeted mice develop obesity concomitant with 
increased fat mass. (A) Percentage of body-weight change after stereotaxic 
surgery of AAV-GFP and AAV-Cre into the mediobasal hypothalamus of 
Snord116fl male mice (mean ± SEM). AAV-Cre–treated mice had a greater 
increase in body weight than AAV-GFP–treated controls. P = 0.016, 2 way 
repeated-measures mixed ANOVA. (B) Individual body-weight curves of 
AAV-Cre–injected mice (n = 21) compared with AAV-GFP–injected mice  
(n = 20). (C) Body-weight histogram of mice at 10 weeks after stereo-
taxic injection. (D) Comparison of AAV-GFP–treated control mouse with 
AAV-Cre–treated mouse from the obese subset. (E) Body composition as 
measured with DEXA in AAV-Cre– and AAV-GFP–treated mice at 10 weeks 
after surgery (mean ± SEM).
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natal life and lower body weights throughout adulthood. Further-
more, we did not observe hyperphagia in the congenital Snord116+/–P 
mice using a previously reported ANCOVA-based method (30) to 
appropriately account for the low body weight of these mice.
Recent work suggests that defects in prohormone processing 
may underlie the appetitive phenotype in PWS, with SNORD116 
deficiency linked to decreased expression of PCSK1 and its 
associated regulator NHLH2 in patient-derived iPSCs as well 
as across several tissues in Snord116+/–P mice 
(24). We observed no differences in hypotha-
lamic Pcsk1 expression in Snord116+/–P mice 
in either ad libitum–fed or fasted states and 
also found no alterations in Nhlh2 expres-
sion. Within the hypothalamus, PCSK1 is 
responsible for processing a number of sub-
strates relevant to energy homeostasis con-
trol, and within the ARC, this interfaces 
with multiple components of the leptin/ 
melanocortin pathway, including POMC, NPY, 
and AGRP in humans (25). Our findings indi-
cate that the expression of these components 
of the arcuate leptin/melanocortin pathway, 
at least in mice, is not perturbed with con-
genital Snord116 deficiency. We observed 
consistent upregulation of Npy, Agrp, and Lepr 
mRNA with fasting in the ARC of both WT and 
Snord116+/–P mice. Npy and Agrp upregulation 
in states of food deprivation has been exten-
sively reviewed (33–35), and leptin receptor 
expression has been reported to increase as 
leptin levels fall during food restriction, occur-
ring preferentially within Agrp rather than 
Pomc neurons (36, 37). Thus, it appears that 
Snord116 is not essential for functional nutri-
tionally regulated transcriptional responses of 
these genes in the ARC. Our results draw par-
allels to human findings highlighting the lack 
of aberrant leptin levels in PWS patients versus 
obese controls (after adolescence) or nonobese 
controls (prior to weight gain) (38–40).
Since mice with congenital Snord116 dele-
tions do not undergo the phenotypic transition 
seen in human PWS, we generated adult-onset 
Snord116 deletions to determine whether phe-
notypes mirroring later stages of human PWS 
(i.e., obesity and hyperphagia) might appear in 
the absence of a developmental growth phe-
notype. An acute adult deletion also excludes 
the effect of compensatory changes that may 
occur as a result of congenital deletions, simi-
lar to that reported for Agrp, where a food-
intake phenotype is evident only in adult, but 
not neonatal, mice (41). We observed that 
adult-onset deletion of Snord116 results in a 
delayed hyperphagia, observed at 9 weeks 
after the stereotaxic surgery. The lag in mani-
festing the phenotype could be due to less effi-
cient Cre-Lox recombination for larger regions (150 kb Snord116 
cluster) (42), which can require a longer period of exposure to Cre 
before sufficient recombination occurs.
While hyperphagia was found in the AAV-Cre–injected 
mice, there was variability in weight, with a subset of mice gain-
ing more than 140% of their starting body weight. We dem-
onstrate that Cre injection specifically diminishes Snord116 
expression in the mediobasal hypothalamus and sought to 
Figure 5. Cre-targeted mice have unaltered hypothalamic leptin-melanocortin gene expression, 
but increased Socs3 expression in obese animals. Box plots of gene expression from laser- 
captured hypothalamic sections from AAV-Cre hits with less than 25% body-weight gain after 
surgery (AAV-Cre, n = 3); AAV-Cre hits with more than 40% body-weight gain after surgery (AAV-
Cre obese, n = 3); and AAV-GFP controls (n = 3). (A–F) Expression of Pomc, Pcsk1, Npy, Nhlh2, Agrp, 
and LepR is unchanged between the AAV-Cre–treated groups and AAV-GFP controls. (G) Expression 
of hypothalamic Socs3 is increased in AAV-Cre obese mice (FDR = 0.08), and (H) expression of Cre 
(FDR = 2.37 × 10–45) and (I) GFP (FDR = 5.55 × 10-22) are only present within the respective treatment 
groups. Data shown are from mice at 10 weeks after surgery with expression as log2 counts per mil-
lion. FDR values were generated using the Benjamini-Hochberg FDR procedure.
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minimize the effects of technical variability by examining viral 
targeting to exclude animals where AAV-Cre was not delivered 
or was only detected unilaterally. Weight variability remained 
present, however, even when we excluded all animals in which 
virus was not expressed in the hypothalamus. While the vari-
ability in body weight seen may have a methodological explana-
tion, other explanations are worthy of consideration. Snord116 
is a paternally expressed gene cluster, and aspects of the cluster 
may crosstalk with other imprinted genes as part of an imprinted 
gene network in neurons (43). Recent reports suggest that dys-
regulation of imprinted gene networks (such as that seen with 
insufficiency of another imprinted gene, Trim28) can lead to 
polyphenism in which both lean and obese phenotypes are 
observed despite the identical underlying genotype and a highly 
controlled environment.
The presence of hyperphagia, concomitant with obesity in a 
subset of mice, after Snord116 deletion in the mediobasal hypo-
thalamus of adults indicates that Snord116 plays a role in the 
hypothalamic control of appetite and food intake. It further pro-
vides a murine model recapitulating aspects of the later stages 
of human PWS, specifically phases 2b and 3, in which weight 
begins to increase in parallel with increased appetite, followed 
by fully fledged hyperphagia (44). We thus propose that the 
developmental and energy homeostasis phenotypes of PWS are 
dissociable in the mouse and that deletion of Snord116 can lead 
to robust hyperphagia in the absence of an early growth pheno-
type (presented in Supplemental Figure 10).
Interestingly, however, these mice seem to increase in weight 
due to hyperphagia without evident changes in energy expendi-
ture. The hyperphagia and obesity in our mouse model further 
contrasts with findings from a tamoxifen-inducible model of 
Snord116 deletion, in which there was no difference in body weight 
and reduced food intake (when corrected for body weight) (45). 
Considering that Cre-Lox recombination may be less efficient 
for the 150-kb Snord116 cluster, a transient exposure to Cre with 
tamoxifen (compared with a sustained exposure to AAV-driven 
Cre expression) might account for some of these differences.
Similar to what was shown in our data from congenital 
Snord116+/–P mice, we did not detect any changes in the expres-
sion of Pcsk1, Nhlh2, or other leptin/melanocortin pathway genes 
in the mediobasal hypothalamus of the hyperphagic Snord116fl 
Cre-injected animals. This suggests that alternative explana-
tions for the hyperphagia of SNORD116 deficiency are required. 
Of interest, we observed that Socs3 expression was significantly 
increased in the hypothalamus of obese AAV-Cre–treated mice 
compared with GFP controls (log2 FC = 2.7). While Socs3 levels 
may increase as a result of obesity in these animals, this increase 
appears to be graded, with nonobese AAV-Cre animals showing a 
trend for increased hypothalamic Socs3 expression (log2 FC = 1.2). 
Socs3 is a negative regulator of leptin signaling and has been pro-
posed to mediate central leptin resistance (31, 46), and mice with 
modestly overexpressed Socs3 in POMC neurons have increased 
body weight and adiposity (47).
In conclusion, we report that adult deletion of Snord116 in the 
mediobasal hypothalamus represents a hyperphagic murine model 
of PWS, with a subset of mice further developing obesity concomi-
tant with increased fat mass. Our work highlights that modulating 
the onset of Snord116 deletion in mice can recapitulate differing 
phenotypes from the natural history of human PWS. This provides 
a unique model for further studies investigating the pathophysiol-
ogy of PWS as well as a platform for testing the efficacy of interven-
tions aiming to prevent or reverse hyperphagia in PWS.
Methods
Animal husbandry, breeding, and genotyping
Animals were housed in a 12-hour light/12-hour dark cycle in a 
temperature-controlled (22°C) facility, with ad libitum access to food 
and water unless stated otherwise. Mice were weaned between P19 
and P21 and were kept on RM3 expanded chow (Special Diet Ser-
vices). All mice were on a C57BL/6J background, with Snord116+/–P 
(B6[Cg]-Snord116tm1.1Uta/J; JAX stock no. 008149) and Snord116fl 
mice (B6[Cg]-Snord116tm1Uta/J; JAX stock no 008118) obtained 
from Jackson Laboratories. Genotyping was performed as previously 
reported (20), with a mix of 3 primers (Sigma Aldrich): WT forward 
(AATCCCCAACCTACTTCAAACAGTC); deletion forward primer 
(TTTACGGTACATGACAGCACTCAAG); and common reverse primer 
(TGGATCTCTCCTTGCTTGTTTTCTC).
Measurement of body mass and composition
For Snord116+/–P mice, postnatal body weight was measured in 3 inde-
pendent mouse litters on scales calibrated to 0.01 g. For adult mice, 
measurements of body weight were performed once per week from 
3 to 16 weeks of age on scales calibrated to 0.1 g. For the mice with 
Snord116 deletion in mediobasal hypothalamus, body weight was mea-
sured daily from 3 days before to 3 days after stereotaxic surgery, after 
which body weight was measured weekly until 10 weeks after surgery 
on scales calibrated to 0.1 g. Body composition was measured using 
DEXA with a Lunar PIXImus Mouse Densitometer (GE Healthcare 
Systems). Prior to DEXA, mice were administered a terminal dose of 
anaesthetic (Dolethal 200 mg/ml solution, Vetoquinol UK Ltd.).
Hypothalamic quantitative PCR
Quantitative PCR (qPCR) was performed on an ABI 7900 real-time 
PCR system on RNA extracted using an miRNeasy RNA Extrac-
tion Kit (QIAGEN) from microdissected mouse hypothalami from 
WT and Snord116+/–P mice using gene-specific primers for Gapdh 
(Mm99999915_g1, TaqMan, Thermo Fisher Scientific), Pcsk1 
(Mm00479023_m1, TaqMan, Thermo Fisher Scientific), and Nhlh2 
(Mm01959164_u1, TaqMan, Thermo Fisher Scientific).
Measurement of food consumption and energy expenditure
Daily food intake was performed with single-housed mice using 
scales calibrated to 0.1 g. For the congenital deletion mice, food 
intake was measured over 10 days in mice between 13 and 15 weeks 
of age. Snord116fl mice undergoing stereotaxic surgery underwent 
2 food-intake studies, a 10-day food-intake study at 2 weeks after 
surgery and a 5-day food-intake study at 9 weeks after surgery. Fast-
refeeding studies were performed after a 24-hour fast, with food 
intake measured at 1, 2, 4, 8, 12, and 24 hours after reintroduction 
of chow or a 45% fat palatable high-fat, high-sugar (HFHS) diet 
(D12451, Research Diets). Metabolic rate measurements were made 
over a period of 72 hours, with animals single-housed in Techniplast 
cages. Animals were single housed 1 week prior to measurement for 
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anti-rabbit, EnVision+ System, Dako), followed by three 10-minute 
washes in TBST. DAB (DAKO Liquid DAB+ Substrate Chromogen 
System) was then applied for 3 minutes before a final wash in water, 
ethanol dehydration, xylene wash, and mounting. Imaging was per-
formed at 20× using a Hamamatsu NanoZoomer S60 digital slide scan-
ner. Successful targeting was defined by the presence of bilateral Cre 
expression within the mediobasal hypothalamic region (bregma –1.22 
to –2.70). Presence of bilateral Cre was scored blindly by 2 researchers, 
and data for all samples are included in Supplemental Figure 7.
Serum profiling
Serum samples were collected from AAV-injected mice via cardiac 
puncture from terminally anesthetized mice at 10 weeks after sur-
gery. Total thyroxine (T4) was measured using a Dimension EXL 
autoanalyser (Siemens). IGF-1 was measured using the Quanti-
kine Mouse IGF-1 ELISA Kit (R&D Systems), and testosterone was 
measured using the Testosterone Mouse ELISA Kit (Demeditec).
Laser-capture microdissection
Snord116+/–P fasted versus ad libitum–fed study. Brains were collected 
from WT and Snord116+/–P mice between 17 and 19 weeks of age across 
2 nutritional states, either ad libitum fed or after a 24-hour fast. Brains 
were fresh frozen and stored at –80°C before cryosectioning on a Bright 
OTF5000 cryostat. Consecutive 20-μm coronal sections were collected 
from 0.34 mm through 2.70 mm caudal to bregma (51) onto glass slides 
(Superfrost Plus, Thermo Fisher Scientific). Fresh-frozen brain sections 
were fixed in 95% ethanol (30 seconds) and rehydrated in an ethanol 
series (75% ethanol, 50% ethanol) prior to staining with cresyl violet 
(Ambion). Sections were then dehydrated in another ethanol series of 
50%, 75%, 95%, and 100% ethanol and left to air dry prior to laser cap-
ture. Four nuclei (PVN, ARC, VMH, DMH) were then dissected from an 
average of 90 serial sections covering the mediobasal hypothalamus in 
mouse from bregma –0.34 to –2.70 mm using a PALM Microbeam Laser 
Capture Microdissection System (Zeiss) on a ×5 objective. Tissues were 
captured on AdhesiveCap Clear PCR tubes (Zeiss) and stored in 80 μl 
of QIAzol (QIAGEN) on dry ice prior to RNA extraction. Laser capture 
and subsequent cDNA library preparation were performed in 3 batches 
of 8 brains. The laser-capture procedure was similar to those used in 
previous reports (52, 53). RNA from laser-captured nuclei was extracted 
using the miRNeasy Micro RNA Extraction Kit (QIAGEN). Samples 
were then run on an Agilent 2100 Bioanalyzer using Agilent RNA 600 
pico and/or nano chips to determine quantity and quality, with a typical 
sample RNA concentration in the range of 1 to 5 ng/μl.
AAV-injected Snord116fl hypothalami. Laser capture was performed 
using the same method as described above on single fresh-frozen brain 
slices, with hypothalamic regions excised based on the pattern of Cre 
immunohistochemistry in adjacent sections. Six AAV-Cre–injected 
mice were used, 3 with body-weight gain of greater than 140% of the 
presurgery weight (obese) and 3 with body-weight gain of less than 
125%, as well as 3 region-matched AAV-GFP controls. Quantity and 
quality were assessed as above, with a typical sample RNA concentra-
tion between 70 and 200 pg/μl.
Library preparation and RNA-seq
Snord116+/–P fasted versus ad libitum–fed study. Total RNA of 2 ng from 
each hypothalamic nucleus was SPIA amplified with an Ovation RNA-
Seq System V2 (NuGEN). cDNA was fragmented to 200 bp using a 
acclimatization, and energy expenditure was monitored on a custom- 
built system (Idea Studios). Oxygen consumption (VO2), carbon 
dioxide production (VCO2), respiratory exchange ratio (VCO2/VO2) 
(RER), and energy expenditure were assessed by the system over 
the course of the run at intervals of 10 to 15 minutes. Four cohorts 
of animals were used for the energy expenditure, each at between 5 
and 6 weeks of the date of surgery. Energy expenditure (EE) in joules 
(J) at every time point was calculated based on indirect calorimetry 
using the Elia and Livesey equation: EE(J) = 15.818 × VO2 + 5.176 × 
VCO2 (48). Energy expenditure measurements in the first 3.5 hours 
at the start of the run were discarded in order for the animals to reach 
a steady state. Food intake and energy expenditure were corrected 
for body weight using ANCOVA (30), which was performed using 
the generalized linear model (glm) analysis in SPSS 23.0 (IBM) with 
body weight as a covariate.
Stereotaxic surgery
Homozygous Snord116fl male mice at 10 to 12 weeks of age were injected 
with AAV viral vectors while under isoflurane anesthesia, similarly to 
the method described previously (49). Viral vectors used were either 
AAV7-CAG-oCre (3 × 1013 vg/ml) for test animals or AA7-CMV-GFP 
(2.1 × 1012 vg/ml). Vectors were generated by Fàtima Bosch’s group and 
utilized similarly to what was indicated in previous reports (50). Virus 
(200 nl) was injected bilaterally into the mediobasal hypothalamus, at 
1.5 mm caudal to bregma (51), and plus or minus 0.28 mm laterally to 
the midline, and 6 mm below the skull. Injections were delivered with a 
5 μl Hamilton syringe, with the needle left in place for 10 minutes after 
viral delivery to prevent reflux of the solution, and then gradually lifted in 
2-minute steps at 4 mm and 2 mm below the skull surface.
Verification of viral targeting
At 10 weeks after surgery, mice were terminally anesthetized with 
Dolethal and brains were excised, frozen on dry ice, and stored at 
–80°C. RNA expression levels of Snord116 in brains of AAV-injected 
mice were tested using qPCR from 1 mm micropunches of the medio-
basal hypothalamus obtained with a biopsy punch (Kai Medical), 
with micropunches of the PVN and the cortex used as controls. RNA 
was extracted using an miRNeasy RNA Extraction Kit (QIAGEN) 
from mouse tissue, and cDNA was generated using the Superscript 
VILO cDNA Synthesis Kit (Thermo Fisher Scientific). qPCR was then 
performed on an ABI 7900 Real-Time PCR System using the gene-
specific primers for Snord116 snoRNA (Mm03455667_s1, TaqMan, 
ABI) and Gapdh (Mm99999915_g1, TaqMan, ABI). For all animals 
included in the metabolic analyses, the presence of Cre was tested 
for with immunohistochemistry on serial 20-μm sections of fresh-
frozen brains. After mounting onto glass slides, tissues were fixed 
overnight in 10% formalin at room temperature. The following day, 
slides were washed once for 5 minutes in TBS, placed into a sealed 
container with 1× target-retrieval solution, pH 9 (Dako), and heated 
to 97°C for 40 minutes. After cooling to room temperature, endog-
enous peroxidase was blocked for 10 minutes, after which tissues 
were washed for 5 minutes in TBS and blocked in antibody diluent 
(1% BSA, 0.3% Triton-X in TBS) for 1 hour before incubating with a 
primary antibody overnight at 4°C (Novagen, catalog 69050, rabbit 
anti-Cre, 1:10,000). Slides were then washed 3 times for 10 minutes 
in 1× wash buffer (TBST, Dako) and incubated for 40 minutes at 
room temperature with a secondary antibody (HRP-labeled polymer 
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Bioruptor Sonicator (Diagenode), followed by end repair and adapter 
ligation with the Encore Rapid DR Multiplex 1-96 Protocol to allow 
multiplex sequencing. Libraries of cDNA were quantified (KAPA 
Quantification Kit) and then submitted to CRUK Cambridge Institute 
(Cambridge, United Kingdom) for sequencing on an Illumina Hi-Seq 
2500 in 2 to 3 lanes. Single-end reads (SE50) from 93 laser-captured 
hypothalamic nuclei were obtained, with an average of 15.63 million 
reads sequenced per sample.
AAV-injected Snord116fl hypothalami. Total RNA of 500 pg from 
each sample was used to prepare cDNA libraries using the Pico Input 
Mammalian SMARTer Stranded RNA-Seq Kit (Takara Bio). cDNA 
libraries were quantified on an Agilent 2100 Bioanalyzer using the 
high-sensitivity DNA kit (Agilent) and then submitted to CRUK- 
Cambridge Institute for sequencing on an Illumina Hi-Seq 4000 in 1 
lane. Single-end reads (SE50) with an average of 9.02 million sequenced 
reads per sample were obtained.
Bioinformatics
Reads were mapped to Mus musculus GRCm38 genome assembly 
(Ensembl) with TopHat, achieving an average mapping rate of 88.67% 
in the Snord116+/P study and 78.81% in the AAV injections study. Repro-
ducible reads have been generated in this manner in orthogonal exper-
iments (54–56). Analysis of RNA-seq data was performed in RStudio 
using the edgeR and limma packages. In the Snord116+/P study, outlier 
samples were detected based on global transcriptomic profiles in multi-
dimensional scaling (MDS) plots using edgeR (57), with 8 of 93 samples 
excluded, so that there were 85 samples across 4 conditions (WT fast, 
WT fed, Snord116+/–P fast, Snord116+/–P fed), resulting in 4 to 6 biological 
replicates for each hypothalamic nucleus within each group. Transcrip-
tomic data sets were deposited in the NCBI’s Gene Expression Omni-
bus database (GEO GSE96627, GSE102992, and GSE106210).
Statistics
Graphs were generated in Graphpad Prism 6.0 or R, with details of the 
statistical tests used provided in the figure legends. Histogram of body 
weight 10 weeks after surgery was generated in R using the easyGg-
plot2 package. Differential gene expression was calculated using the 
glm functionality in EdgeR. SPSS 23.0 (IBM) was used to run ANOVA 
and ANCOVA tests. Unless otherwise noted, significance is defined at 
FDR < 0.1 and/or P < 0.05.
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